Therapeutic Effects of R-IDARAM and Intrathecal Immunochemotherapy on Elderly Patients With PCNSL
Trial statusRecruiting
Trial phasePhase 2, Phase 3
Trial typeInterventional
Biological sexAll
Age60-75
SponsorNavy General Hospital, Beijing
About this trial
This study suggests that R-IDARAM combined with intrathecal immunochemotherapy may be high effective in elderly patients with primary central nervous system lymphoma (PCNSL).
Eligibility criteria
Qualifiers
Newly diagnosed histologically proven non-Hodgkin's lymphoma (NHL).
Disqualifiers
Involved sites other than the brain, meninges, CSF, or the eyes.
Age less than 18 years or greater than 75 years.
Inadequate bone marrow capacity (defined as neutrophils<1.5 ×10^9/L, platelets <100 ×10^9/L, and hemoglobin level< 8 g/dL).
Known cause of immunosuppression (ie, HIV type I infection).
Trial design
Treatments tested in this trial
- R-IDARAM plus intrathecal chemotherapy
Treatment groups
100 Participants
are divided into 1 treatment groupSponsors and collaborators
Source ClinicalTrials.gov